Aberrant Upregulation of 14-3-3σ and EZH2 Expression Serves as an Inferior Prognostic Biomarker for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world. It is of important significance to find biomarkers for the prognostic monitoring of HCC. The 14-3-3σ and EZH2 proteins are involved in cell cycle regulation and epigenetic silencing. We herein examined the significance of 14-3-3 σ and EZH2 in HCC (n = 167) by immunohistochemistry, RT-PCR and qRT-PCR. The correlation between 14-3-3σ and EZH2 expression and patients' clinicopathologic features were examined, as was the correlation between 14-3-3σ and EZH2 expression and the prognosis of HCC patients. We found that 14-3-3σ and EZH2 were highly expressed in HCC (71% and 90%), the expression of EZH2, but not 14-3-3σ, is associated with vascular invasion and tumor differentiation (p<0.01). The coexistence of 14-3-3σ and EZH2 overexpression is associated with a relatively unfavorable prognosis (p<0.01), suggesting that aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for HCC.

[1]  T. Utsunomiya,et al.  Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma , 2005, British Journal of Cancer.

[2]  Mong-Hong Lee,et al.  Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.

[3]  Y. Nakanuma,et al.  The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma , 2008, Laboratory Investigation.

[4]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[5]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Chrousos,et al.  Vpr Protein of Human Immunodeficiency Virus Type 1 Binds to 14-3-3 Proteins and Facilitates Complex Formation with Cdc25C: Implications for Cell Cycle Arrest , 2005, Journal of Virology.

[7]  P. Lara,et al.  Hypermethylated 14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis , 2010, BMC Cancer.

[8]  M. Kazemi,et al.  Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: A potential biomarker for detection of breast cancer in patients , 2012, Advanced biomedical research.

[9]  S. Edwards,et al.  Vitronectin induces migration of activated T lymphocytes , 2000 .

[10]  V. Pirrotta,et al.  Polycombing the Genome: PcG, trxG, and Chromatin Silencing , 1998, Cell.

[11]  I. Ng,et al.  EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers , 2013, PloS one.

[12]  K. Kinzler,et al.  14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.

[13]  R. van Driel,et al.  Characterization of Interactions between the Mammalian Polycomb-Group Proteins Enx1/EZH2 and EED Suggests the Existence of Different Mammalian Polycomb-Group Protein Complexes , 1998, Molecular and Cellular Biology.

[14]  K. Kinzler,et al.  14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. , 1999, Nature.

[15]  Jun Lu,et al.  Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis , 2010, Medical oncology.

[16]  Hiromu Suzuki,et al.  Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma , 2000, Oncogene.

[17]  L. Colleaux,et al.  The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders , 2000, European Journal of Human Genetics.

[18]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[19]  Jie Xu,et al.  Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer , 2011, BMC Cancer.

[20]  C. Bödör,et al.  Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors , 2012, Diagnostic Pathology.

[21]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.